Introduction
In recent years the suppressive action of 1,25-dihydroxyvitamin D (l,25-(OH)2D3)' on PTH synthesis and secretion has been well defined. Primary cultures ofbovine parathyroid cells have been used to demonstrate that 1,25-(OH)2D3 inhibits release of PTH (1, 2) , decreases the levels ofpre-proPTH mRNA (3) , and blocks transcription of the PTH gene (4) . Silver et al. confirmed this inhibition of transcription in vivo by administration of a dose of 1,25-(OH)2D3 that did not raise serum calcium (5) . The close correlation between PTH release and the decrease in pre-proPTH mRNA, and the lack of an acute effect of 1,25-(OH)2D3 in cell culture suggested that the major action of 1,25-(OH)2D3 is at the transcriptional level (1) . Furthermore, since physiological concentrations (10-11 M) of 1,25-(OH)2D3 in the culture medium suppressed release and synthesis of PTH, it seems likely that conditions in which 1,25-(OH)2D3 levels are abnormally low (e.g., renal failure) would lead to increases in serum PTH.
The suppressive effect of 1,25-(OH)2D3 on PTH secretion has lead to the use of this vitamin D metabolite for treatment of secondary hyperparathyroidism. Administration of 1,25-(OH)2D3 was found to lower PTH levels in hemodialysis patients more effectively than calcium, even when both substances raised ionized calcium to the same degree (6) . These findings are consistent with those of Brown et al., who found that parathyroid cells from patients with secondary hyperparathyroidism are less sensitive to the suppressive effects of calcium (7) , and those of Delmez et al., who have recently reported that intravenous 1,25-(OH)2D3 treatment of renal failure patients shifts the set point for calcium toward a more normal value (8) . Although 1,25-(OH)2D3 is now commonly used to treat secondary hyperparathyroidism associated with renal failure, its prolonged use is precluded in some cases by hypercalcemia (9-1 1).
A number of analogues of 1,25-(OH)2D3 have been synthesized that have little calcemic activity but retain the ability to differentiate myeloid leukemia cells. Ostrem et al. reported that 24-homo-1,25-(OH)2D3 could differentiate HL-60 cells but did not increase serum calcium when administered to vitamin D-deficient rats (12) . Binderup Denhardt's, 100 Ag/ml salmon testes DNA, and 10% dextran sulfate in 50% formamide containing 106 cpm/ml of either the PTHm 122 probe or the (3-actin oligonucleotide probe. The hybridization was carried out overnight at the less stringent room temperature since there are differences in the DNA sequence between the human PTH cDNA probe and the rat pre-proPTH mRNA. The filters were washed the next day at room temperature once in 4X SSC, 0.1% SDS and three times in 1X SSC, 0.1% SDS before drying and subsequent autoradiography. Again, this is a less stringent wash so as not to obliterate the species difference between the cDNA probe and the desired measurement of mRNA. As a control, cytoplasmic RNA extracts from 10 mg of rat liver, prepared as described above, were assayed in an identical manner.
Northern blot analysis. A portion of the cytoplasmic RNA pool extracted from the rat parathyroid glands was treated with phenol and ethanol was precipitated with carrier tRNA and subjected to electrophoresis on a 1.2% agarose gel containing formaldehyde. The RNA was transferred to nitrocellulose by capillary action, and the nitrocellulose was baked, prehybridized, and hybridized as described above. The migration of ribosomal RNA was determined by ethidium bromide staining of an adjacent lane in the agarose gel containing a liver RNA extract.
Results
Calcemic response to 1,25-(OH)2D3 and OCT. The calcemic activity of OCT was examined in normal rats and compared with that for 1,25-(OH)2D3. Rats received a single intraperitoneal injection of vehicle (250 Ml propylene glycol) or various doses ofeither 1,25-(OH)2D3 or OCT, and plasma calcium was measured 24 h later. As shown in Fig. 1 , doses of OCT up to 1 ,ug (4 Mg/kg body weight) did not increase plasma calcium, whereas 1,25-(OH)2D3, as expected, raised plasma calcium in a dose-dependent manner with an increment of 1.4 mg/dl at the l-,ug dose.
To evaluate more chronic administration, normal rats received vehicle or 0.5 ug (1.7 Mg/kg body weight) of 1,25-(OH)2D3 or OCT daily for 4 d. Fig. 2 shows that even with prolonged treatment with OCT, plasma calcium did not increase. In contrast, rats receiving a comparable dose of 1,25-(OH)2D3 became very hypercalcemic, and by 4 d calcium had increased by 3 mg/dl. Thus, it is clear that OCT has little if any calcemic activity in vivo as reported previously (15) .
PTH secretion by cultured bovine parathyroid cells. OCT was initially tested for its ability to suppress PTH release from primary cultures of bovine parathyroid cells. We and others have shown previously that 1,25-(OH)2D3 suppresses PTH secretion, and that prolonged exposure (> 24 h) to the hormone is required to observe this effect (1, 2) . Therefore, we incubated the parathyroid cultures for 48 h with various doses of OCT and compared the suppression with that obtained with 1,25-(OH)2D3. Fig. 3 shows a dose-response curve for suppression ofPTH by OCT and 1 ,25-(OH)2D3. Both compounds 4 each morning, blood DAYS was drawn and the next injection given. All values are expressed as mean±SEM, n = 6. Statistical differences at each time point were determined by t test. P < 0.001 was observed at each time for both control vs. 1,25-(OH)2D3-treated rats and OCT vs. 1,25-(OH)2D3-treated rats. No significant differences were observed between control and OCT-treated rats at any time point.
suppressed the release of PTH in a dose-dependent fashion. In three independent experiments PTH was reduced by 30-35% by both 1,25-(OH)2D3 and OCT at 10-8 M (P < 0.05). Although OCT appeared to be slightly more inhibitory at intermediate concentrations, the difference was not statistically significant.
Suppression ofpre-proPTH mRNA levels in vivo. The suppressive activity of OCT on the parathyroid glands was tested in vivo. It is well established that 1,25-(OH)2D3 inhibits the transcription ofthe PTH gene in vivo (5) , and that the decrease in pre-proPTH mRNA accounts, at least in part, for the suppression of PTH release by parathyroid cells. Therefore, we measured the levels of pre-proPTH mRNA in rat parathyroid glands 48 h after treatment with vehicle or 40 ng (0.13 ,g/kg body weight) of either OCT or 1,25-(OH)2D3. This low dose was necessary since higher amounts of 1,25-(OH)2D3 will raise serum calcium, which can also decrease the levels of preproPTH mRNA (20) . In this experiment pre-and posttreatment calcium values were 8.66±0.07 and 8.67±0.10 mg/dl in the 1 ,25-(OH)2D3-treated rats and 8.51±0.10 vs. 8.48±0.09 for the OCT-treated rats.
Pre-proPTH mRNA could be detected reproducibly by slot blot analysis of the cytoplasmic RNA extract from as little as one-fourth of a normal rat parathyroid gland (Fig. 4, left) . No hybridizable RNA was detected in cytoplasmic mRNA extracts from rat liver (Fig. 4) . Treatment with either 1,25-(OH)2D3 or OCT caused a marked reduction in the hybridizable PTH mRNA per parathyroid gland (Fig. 4) . As seen in Fig. 4 (right) , the amounts of 13-actin mRNA were the same PTH Figure 4 . Slot blot analysis of cytoplasmic RNA extracted -actin from liver, and from parathyroid glands from control, in the parathyroid gland extracts from all three groups, indicating that equivalent amounts of RNA were applied to each slot. The higher amount of hybridization of the ,3-actin probe to the liver mRNA is due to heavier loading ofthis sample. On the average there was a 70% reduction in the hybridizable pre-proPTH mRNA by treatment with either OCT or 1,25-(OH)2D3 compared with control. Northern blot analysis of the RNA extracts revealed that the bulk of the hybridizable pre-proPTH mRNA species have a size of -850 bases (Fig. 5 , arrow), using ribosomal RNA at 4,780 and 1,870 bases as standard, which is consistent with the estimates ofthe rat PTH message. There appears to be a small amount ofdegradation of the mRNA during preparation as evidenced by the hybrid signal -300 bases in size. Again there is more hybridizable mRNA present in the extracts of normal glands compared with the extracts obtained from rats treated with 1,25-(OH)2D3
or OCT.
Discussion
The ability of 1 ,25-(OH)2D3 to feed back on the parathyroid glands to suppress PTH is well established. The parathyroid glands were shown to be target tissues for 1,25-(OH)2D3 by Henry and Norman by in vivo labeling of this tissue with tritiated ligand (21) . Subsequent studies by Brumbaugh, (4) and as early as 3 h in rats after intraperitoneal injection of 1,2540H)2D3 (5) .
The suppressive activity of 1,25-(OH)2D3 on PTH has been used clinically for the treatment of secondary hyperparathyroidism (6), but in some cases prolonged administration can lead to hypercalcemia (9) (10) (11) . For this reason we tested the noncalcemic 22-oxa analogue of 1,25-(OH)2D3 for its activity in suppressing PTH. We found that this analogue (OCT) was capable of suppressing PTH release from cultured parathyroid cells in a dose-dependent manner. In fact, it appeared to be slightly, but not significantly, more active than the parent compound. The affinity of OCT for the chick intestinal receptor was reported to be 14 times less than that for 1,25-(OH)2D3 (15) , but the relative binding affinities of these two compounds for the 1,25-(OH)2D3 receptor in parathyroid cells are not yet known.
We also showed that OCT is active in vivo and, like 1,25-(OH)2D3, decreases pre-proPTH mRNA levels. Thus, the lack of calcemic activity is not the result of rapid metabolism or clearance of OCT. Abe and co-workers have also demonstrated activity of OCT on modulation of the immune response in vivo (24) . The problem of hypercalcemia with large doses of 1,25-(OH)2D3 has spurred the development of vitamin D analogues that retain the desired activity with little, if any, calcemic activity. A number of analogues of 1,25-(OH)2D3 have recently been developed that retain the cell-differentiating activity of the parent hormone with very low, if any, calcemic activity. Ostrem and co-workers reported that homo analogues of 1,25-(OH)2D3 with extra carbons in their side chains can differentiate the human myeloid leukemia cell line, HL-60, to a monocytic cell type, with much lower calcemic activity than 1,25-(OH)2D3 (12) . Similarly, an analogue of 1,25-(OH)2D3, MC903, with a cyclopropyl group at the end of the side chain was shown to differentiate U937 cells with very little calcemic activity (13) . The latter has been shown to be very effective in treating psoriasis. The analogue used in the present study, OCT, was previously found to retain the activity of the parent compound to differentiate HL-60 cells with little calcium mobilizing activity in vitro (14) or in vivo (15) . The ability of OCT to suppress PTH synthesis and secretion is another example of the selective activities of these vitamin D analogues. The mechanism of this selectivity is not known. The mechanism currently accepted for 1,25-(OH)2D3 receptor action assumes that receptors are identical in all cell types and thus the intestine and bone would be expected to respond to OCT as the parathyroid glands do. Therefore, other factors such as tissue-specific uptake or metabolism may be responsible for the selective activity of OCT. These vitamin D analogues will be valuable tools for defining further the role of the ligand structure in determining the target gene specificity of the receptor complex.
From the clinical point of view OCT may be a valuable agent for the treatment of secondary hyperparathyroidism. Control of serum phosphorus is mandatory before vitamin D is administered to uremic patients. Since phosphate binders containing aluminum frequently induce aluminum accumulation, with its well-known deleterious effects calcium carbonate is currently the phosphate binder of choice (25) (26) (27) (28) . Unfortunately, the simultaneous administration of large doses of calcium carbonate and 1,25-(OH)2D3 frequently induces severe hypercalcemia precluding the administration oftherapeutic doses of 1,25-(OH)2D3. Thus, the use of an analogue of vitamin D without a calcemic effect but with the same action on parathyroid synthesis and release as 1,25-(OH)2D3, may provide a unique therapeutic tool in the treatment of secondary hyperparathyroidism in patients with chronic renal failure.
